Result of AGM

RNS Number : 4641I

Ovoca Bio PLC

08 August 2019

 

8 August 2019

Ovoca Bio plc

("Ovoca" or the "Company")

Result of AGM

Ovoca Bio plc (LSE: OVB; ISE: OVXA) wishes to announce that each of the resolutions proposed at its Annual General Meeting held in Dublin earlier today were approved by shareholders.

The full text of each resolution was set out in the Notice of Annual General Meeting circulated to shareholders on 28 June 2019.

ENDS

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel [phone]

[e-mail]

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: [phone]

About IVIX: 

IVIX, a Russian‐incorporated company, was formed in 2012 and since that time has sought to develop and subsequently commercialize a proprietary drug candidate, BP-101 (known as "Libicore"), for the treatment of female sexual dysfunction. Libicore is a novel synthetic peptide, administered through a nasal spray. Clinical studies completed to-date have demonstrated statistically significant efficacy in the treatment of a major form of female sexual dysfunction. So far, IVIX has reached and completed Phase III clinical studies in Russia for Libicore. It now intends to seek approval for the marketing of Libicore in the Russian market, as well seek to expand its use internationally.

 

END

 

 

RAGBUGDIGBGBGCI